U.S. Patent Trial and Trademark Appeal Board Decides to Institute Inter Partes Review of United Therapeutics’ Tyvaso® Patent
August 12, 2021 08:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR)...
Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 07:00 ET
|
Liquidia Corporation
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunityResubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powderImproved balance sheet with...
Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021
August 03, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021....
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
June 02, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)...
Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and...
Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration
May 24, 2021 16:05 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of...
Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 07:00 ET
|
Liquidia Corporation
- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery- Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder- Improved financial position...
Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
May 10, 2021 06:30 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the...
Liquidia Corporation to Report First Quarter 2021 Financial Results on May 13, 2021
May 06, 2021 07:00 ET
|
Liquidia Corporation
MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The...
Liquidia Corporation Announces $21.7 Million Private Placement
April 13, 2021 07:00 ET
|
Liquidia Corporation
RESEARCH TRIANGLE PARK, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain...